Covidien divests specialty chemicals business

This article was originally published in The Tan Sheet

07 Jun 2010
News

Executive Summary

The diversified device, medical supply and drug maker will divest its specialty chemicals business to an affiliate of New Mountain Capital LLC for $280 million under an agreement announced May 26. The division, which generated sales of $414 million in fiscal 2009, makes chemicals and related products for research and quality control labs, and for manufacturing in pharmaceutical, biotechnology and other industries. The sale is part of Covidien's strategy to sell businesses outside health care since its spin-off from Tyco in 2007

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS104173

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS104173

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Covidien divests specialty chemicals business

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert